ctDNA Monitoring in Early Breast Cancer
NCT04353557 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2024-07-18
Summary
This is a observational, single center study, monitoring the circulating tumor DNA (ctDNA) in patients with early breast cancer and assessing the prognostic value and treatment outcome monitoring of ctDNA.
Conditions
Sponsors & Collaborators
-
Army Medical University, China
collaborator OTHER -
Geneplus-Beijing Co. Ltd.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-11-29
- Primary Completion
- 2025-06-30
- Completion
- 2026-12-31
Countries
- China
Study Locations
More Related Trials
-
Circulating Tumor DNA as Marker of Therapeutic Efficacy in Breast Cancer Patients
NCT03881384 ·Status: UNKNOWN
-
Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis
NCT05730010 ·Status: COMPLETED
-
Application of CfDNA Methylation Detection in Auxiliary Diagnosis of Breast Cancer
NCT06876610 ·Status: RECRUITING
-
Clinical Application of ctDNA in Early Screening of Breast Cancer
NCT03973034 ·Status: UNKNOWN
-
Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients
NCT05326295 ·Status: RECRUITING
-
Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
NCT03688035 ·Status: UNKNOWN
-
Genetic Markers of Circulating Tumor DNA for Monitoring Breast Cancer Patients in Costa Rica
NCT04163159 ·Status: UNKNOWN
-
Clinical Application of CTDNA in Operable Breast Cancer Patients
NCT02797652 ·Status: UNKNOWN
-
Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment
NCT06087120 ·Status: RECRUITING
-
Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR
NCT03947736 ·Status: UNKNOWN
-
Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer
NCT06706557 ·Status: RECRUITING
-
Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery
NCT05914792 ·Status: ACTIVE_NOT_RECRUITING
-
Prognostic Value of Circulating Tumor DNA Dosing in Patients in Neoadjuvant Breast Neoplasia
NCT05050890 ·Status: UNKNOWN
-
Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers With Regional Nodal Irradiation for Breast Cancer
NCT04308720 ·Status: ACTIVE_NOT_RECRUITING
-
Study of Metabolites Markers in Adjuvant Breast Cancer
NCT03367208 ·Status: COMPLETED
-
Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy
NCT03709134 ·Status: COMPLETED
-
Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients
NCT06479460 ·Status: RECRUITING
-
The Effect of Digital Breast Tomosynthesis in Breast Cancer Long-term Survival: a Single Institution Study
NCT05600257 ·Status: COMPLETED
-
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
NCT05770531 ·Status: RECRUITING ·Phase: PHASE2
-
Detecting Circulating Tumor Cells (CTCs) and Cell Free DNA (cfDNA) in Peripheral Blood of Breast Cancer (BC) Patients to Develop the Clinical Application for Early Detection and Diagnostics
NCT03511859 ·Status: UNKNOWN
-
Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer
NCT02743910 ·Status: ACTIVE_NOT_RECRUITING
-
Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer
NCT03161834 ·Status: WITHDRAWN
-
ScreenIng of Genetic Susceptibility Genes for Breast Cancer Patients in CHinese communiTies
NCT04265937 ·Status: RECRUITING
-
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
NCT07025785 ·Status: RECRUITING ·Phase: NA
-
Prognostic Value of Biomarkers in HR + / HER2 - Advanced Breast Cancer
NCT04683770 ·Status: UNKNOWN